MedeliX
Start asking

Dexamfetamine

Philla · ATC code N06BA02

Also known as: Dexamfetamin, Deksamfetamin, Desamfetamina, Dexamfétamine, Dexanfetamina · Brand names: Attentin, Dexamfetamin Orifarm, Dexamfetamin Sea Pharma, Dexamfetaminhemisulfat Waymade B.V, Philla

Key facts
Active substance
Dexamfetamine
ATC code
N06BA02
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-11-03

Boxed warning

Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine sulfate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine sulfate treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction (see WARNINGS and DRUG ABUSE and DEPENDENCE)

.

Key facts

Dexamfetamine (US name dextroamphetamine) is a sympathomimetic amphetamine with CNS stimulant activity. Per the US label the tablets are used for narcolepsy and for attention deficit disorder with hyperactivity (ADHD) in pediatric patients aged 3 to 16 years.

What it is used for

  • Narcolepsy
  • ADHD in pediatric patients aged 3 to 16 years, as an integral part of a total treatment program (psychological, educational, social measures)

Dosing

  • Use the lowest effective dosage, adjusted individually; avoid late evening doses because of insomnia
  • Narcolepsy: usual dose 5 mg to 60 mg per day in divided doses; ages 6 to 12 start 5 mg daily, 12 years and older start 10 mg daily, raised weekly by 5 mg or 10 mg respectively
  • ADHD ages 3 to 5: start 2.5 mg daily, raised by 2.5 mg at weekly intervals
  • ADHD ages 6 and older: start 5 mg once or twice daily, raised by 5 mg at weekly intervals; only rarely more than 40 mg per day
  • First dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours
  • Not recommended under 3 years of age; assess cardiac disease and tics before starting

Contraindications

  • Known hypersensitivity to amphetamine products
  • During or within 14 days after monoamine oxidase inhibitors (risk of hypertensive crisis)
  • Pheochromocytoma or a history of pheochromocytoma

Important warnings

  • Boxed warning: high potential for abuse and misuse, which can lead to substance use disorder including addiction, overdose and death; assess and reassess risk throughout treatment
  • Sudden death in patients with structural cardiac abnormalities or serious cardiac disease; avoid use in these patients
  • Increases blood pressure and heart rate; monitor for tachycardia and hypertension
  • Psychosis, induction of mania (screen for bipolar risk factors), new tics or worsening of Tourette's syndrome
  • Growth suppression in children (monitor weight and height); lowered seizure threshold; peripheral vasculopathy including Raynaud's phenomenon
  • Serotonin syndrome with serotonergic drugs or CYP2D6 inhibitors

Side effects

  • Palpitations, tachycardia, elevated blood pressure; isolated reports of cardiomyopathy with chronic use
  • Overstimulation, restlessness, insomnia, dizziness, tremor, headache, euphoria or dysphoria; rare psychotic episodes
  • Dry mouth, unpleasant taste, diarrhea, constipation, anorexia and weight loss; intestinal ischemia
  • Impotence, changes in libido, frequent or prolonged erections; urticaria; rhabdomyolysis

Interactions

  • MAO inhibitors: slowed amphetamine metabolism with hypertensive crisis and malignant hyperpyrexia, contraindicated
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tricyclics, fentanyl, lithium, tramadol, St. John's Wort) and CYP2D6 inhibitors: serotonin syndrome risk; start low and monitor
  • Acidifying agents lower and alkalinizing agents (sodium bicarbonate, acetazolamide) raise amphetamine levels
  • May antagonize antihypertensives and antihistamine sedation; tricyclics can potentiate cardiovascular effects
  • Chlorpromazine, haloperidol and lithium inhibit the stimulant effects

Pregnancy and breastfeeding

  • Use in pregnancy only if the potential benefit justifies the potential risk to the fetus; infants of amphetamine-dependent mothers have increased risk of premature delivery, low birth weight and withdrawal symptoms
  • Amphetamines are excreted in human milk; mothers should refrain from nursing

Summary of the official product information, written with AI on 2026-11-03. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Germany

  • AttentinMedice Arzneimittel Pütter Gmbh & Co. Kg · 1 register entry
  • Dexamfetamin OrifarmOrifarm Healthcare A/S · 1 register entry
  • Dexamfetamin Sea PharmaSea Pharma Ab · 1 register entry
  • Dexamfetaminhemisulfat Waymade B.VWaymade B.V. · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Austria

  • PhillaMedice Arzneimittel Pütter Gmbh & Co. Kg · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Brand names in 15 more European countries
Belgium
Adhesa, Attentin
Denmark
Adhesa, Attentin, Dexamfetamin Sea Pharma, Dexamfetamine "afortas", Dexamfetamine Afortas, Dexamfetaminsulfat Waymade, Dexatin, Dexfarm
Estonia
Tentin
Finland
Adhesa, Attadex, Attentin, Dexamfetamin Sea Pharma, Dexamfetamine Afortas, Dexfarm
France
Tentin
Iceland
Attentin, Dexamfetamine Taw Pharma (Ireland)
Italy
Amfexa
Luxembourg
Attentin
Malta
Dexamfetamine Sulfate
Netherlands
Adhesa, Attenfarm, Dexamfetamine A.Forall, Dexamfetamine Sea Pharma, Dexamfetaminesulfaat Dmb Tiofarma, Dexamfetaminesulfaat Waymade, Tentin
Norway
Attentin, Deksamfetamin Waymade B.V., Dexamfetamin Sea Pharma, Dexamfetamine Afortas, Dexamfetamine Taw Pharma, Dexatin, Dexfarm
Poland
Tentin
Portugal
Tentin
Spain
Tentin
Sweden
Attentin, Dexamfetamin Sea Pharma, Dexamfetamin Waymade, Dexamfetamine Afortas, Dexatin, Dexfarm

EMA – Article 57 product data (EU/EEA), 2026-11-03

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. DEXTROAMPHETAMINE SULFATE (SUNRISE PHARMACEUTICAL, INC.) – Prescribing Information, 2026-08-04. DailyMed (NLM), 2026-11-03. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b3a40f-b7ac-4047-8ff5-3e34c2d75193
  2. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database

Editorial: Medelix editorial team · last updated 2026-11-03 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.